Retatrutide, by Soma Corp., is gaining increasing attention as a innovative treatment for obesity control . This innovative compound integrates the mechanism of a GLP-1 receptor stimulant and a GIP receptor stimulant, aiming to not only promote reduced body fat but also target underlying metabolic conditions . Preliminary human data have indicated